Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Scientists identify a way to reverse drug resistance by rewiring the inner workings of leukemia cells

Scientists identify a way to reverse drug resistance by rewiring the inner workings of leukemia cells

Researchers discover a novel signaling pathway that defines interferon responses in blood cancers

Researchers discover a novel signaling pathway that defines interferon responses in blood cancers

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

City of Hope's late-breaking clinical trial data to be presented at AACR

City of Hope's late-breaking clinical trial data to be presented at AACR

Decisive role of PDK1 enzyme in acute myeloid leukemia revealed

Decisive role of PDK1 enzyme in acute myeloid leukemia revealed

Understanding a New Mutation in Pediatric AML

Understanding a New Mutation in Pediatric AML

Scientists identify a promising strategy for stopping Ebola virus polymerase

Scientists identify a promising strategy for stopping Ebola virus polymerase

20% of childhood AML cases associated with rare genetic changes inherited through family bloodlines

20% of childhood AML cases associated with rare genetic changes inherited through family bloodlines

New discovery points to potential drug targets for ASXL1-mutant chronic myelomonocytic leukemia

New discovery points to potential drug targets for ASXL1-mutant chronic myelomonocytic leukemia

Discovery may open novel avenues to prevent or treat hematological malignancies

Discovery may open novel avenues to prevent or treat hematological malignancies

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Tumor cells’ 'ferroaddiction' can be exploited to deliver powerful anticancer drugs

Tumor cells’ 'ferroaddiction' can be exploited to deliver powerful anticancer drugs

Researchers examine how structural violence can set the stage for poorer leukemia outcomes

Researchers examine how structural violence can set the stage for poorer leukemia outcomes

Study provides insight into what causes therapy failure in patients with myelodysplastic syndromes

Study provides insight into what causes therapy failure in patients with myelodysplastic syndromes

Study reveals how the immune system can be triggered to attack cancer cells

Study reveals how the immune system can be triggered to attack cancer cells

Study reveals how the immune system can be triggered to fight cancer cells

Study reveals how the immune system can be triggered to fight cancer cells

HIV patient treated with blood stem cell transplant for leukemia achieves long-term remission

HIV patient treated with blood stem cell transplant for leukemia achieves long-term remission

New mutation may define a high-risk subtype of pediatric acute myeloid leukemia

New mutation may define a high-risk subtype of pediatric acute myeloid leukemia

New high-risk subtype of relapsed pediatric AML revealed

New high-risk subtype of relapsed pediatric AML revealed

Optical genome mapping holds potential to become an important component of leukemia diagnostics

Optical genome mapping holds potential to become an important component of leukemia diagnostics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.